Cancer Genetics — IPO Roadshow (July 2013)
36 slides from Cancer Genetics's IPO roadshow presentation, Jul 29, 2013
Slide 1: Empowering Personalized Cancer Treatment
Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333-189117 July 29, 2013 Empowering July TREATMENT CANCER PERSONALIZED EMPOWERING 29, 2013 GENETICS Personalized Cancer Treatment
Slide 2: Forward-Looking Statements
Forward-Looking All services, Any looking Forward-looking regulatory the Actual The 2013Securities statements Company statements Cancer results statements. along approvals, Genetics, and may disclaims pertaining with that statements Exchange Statement differ are other need Inc. not any materially to
Slide 3: Free Writing Prospectus Statement
Freeor This We you You offering. we 212-813-1010, 2013have should may Writing presentation Cancer anyfiled get underwriter read these Prospectus Genetics, ae-mail: registration the highlights documents preliminary participating prospectus@aegiscap.com. Inc. Statement |statement basic OTCQB: forprosp
Slide 4: Offering Summary and Use of Proceeds
Issuer Exchange Offering Over-Allotment Fully Use Mayo Product Retire Continued General Sole *Lead price 2013 Share of Book-Runner Co-Manager of Cancer Diluted Clinic Cancer Mezzanine Proceeds numbers $11.60. Commercialization Working Summary Size OTCQB R&D Joint Genetics, Shares $15,000,000 Genetic
Slide 5: Growth-Stage, Hybrid Portfolio Company
Growth-Stage, Hybrid Portfolio ~50% Experienced Category Established 2013 Cancer revenue business of continues multi-year collaborations commercially management Genetics, growth Oncology-Focused, model to experience first track Inc. providing team, available, and half | record OTCQB: partnerships 20
Slide 6: Our Molecular Diagnosis Approach
Molecular Our DIAGNOSIS Use Do Assist Personalize What Integrated PATIENTS PHYSICIANS PAYORS PHARMA 2013Iunique genomics have Cancer are drug(s) in patient my Benefit cancer Molecular Diagnostics See Receive focus therapeutic Genetics, survival to PROGNOSIS to Gain high give, outcome provide and & f
Slide 7: Integrating Genomics into Personalized Medicine
CGI’s Traditional Phenotypic Morphologic Large Significant Success 25% Our Biomarkers Genomic Reduced Improved Target 100% Situation Source: Integrating Improve 2013Approach: Cancer & Mission Success Clinical Rate Multiple Care Size Today Analysis Diagnoses Approach & Delays &and Genetics, & in Deli
Slide 8: Unique, Proprietary Products and Services
Unique, PROPRIETARY Proprietary CLINICAL Differentiated BIOPHARMA Biomarker Suite 2013 Cancer of Products Scalable and molecular SERVICES Genetics, and PARTNERSHIPS companion PRODUCTS and complete Multifaceted Services diagnostics Inc. diagnostic | disease-focused OTCQB: Provides &Business FISH deve
Slide 9: Our Target Markets
Our Lymphoma, Hematological: 149,990 Kidney, Urogenital: 36% 376,310 Cervical, Gynecological: 16% 84,140 Death (U.S.) Source: 31% 5*Does Ability 2013 Products Target Estimated Cancer Rate not to American Bladder Endometrial Impact include Launched Markets Leukemia, Genetics, New &Over Cancer routine
Slide 10: Proprietary Products and Development Pipeline
5 Proprietary Commercially Research Clinical Discovery MatBA®—Chronic FHACT™- FHACT™—Cervical* UroGenRA™-Prostate UroGenRA™—Bladder UroGenRA™—Kidney MatBA®—MM MatBA®—FL &Neck 2013 Cancer UGenRA™—Cervical Collaboration &Development Head Clinical Genetics, Diagnostic Launched *—Launched & Commercial &
Slide 11: Hematologic Cancers Still Rising, Survival Improved
52013 Despite Identified (US 20.5 20.0 89 7.9 11.1 12.6 15.5 12 1 7.1 100 18.5 8.7 NumberOnly, Source:21.2 19.7 6.9 8.2 Improved 5.6 2ofLeukemia Genomics-Based 80Cancer 60 7.3 per 6.2 Genzyme 30 2100,000) Years Cancer & Genetics, 1975 Ago Tests & Lymphoma Nature 1985 Care, Incidence Inc. like1995 Ca
Slide 12: MatBA-CLL/SLL Impact
42013 MatBA®-CLL/SLL Impact (Current Favorable 38% Intermediate Favorable/ (no 8% Genomic distinction) of aof cases favorable Validatedon cases Additional20 Method) Aberrations Cancer therapy in with 85% in 39% our prognosis unfavorable (CGI selection Validationsstudy Array-CGH Reported Collaboratio
Slide 13: MatBA-CLL/SLL Risk Stratification
MatBA® MatBA®- Being 20 Poor Intermediate Detection CLL/SLL Patients Provides Surviving –Proportion Time 2013 GOOD INTERMED POOR key outcome Cancer (months) actively genetic classified (n=47) additional (n=74) Can of by PCLL GOOD P<specific = outcome Genetics, MatBA®-CLL/SLL 0.001 =Group used events
Slide 14: UroGenRA-Kidney
UroGenRA™-Kidney Men PROBLEM UroGenRA™ SOLUTION Prospective Approaching Demonstrated J. Retrospective Test In-silico Subtype Tested pRCC Clinical Time 2013 Coleman to and Cancer to(n=75) to distinguish Treatment Benefits Specificity validation women subtype (MSKCC) ongoing Genetics, 100% 97% ongoing
Slide 15: FHACT - Cervical Cancer Test
FHACT™—A Cervical 90% HPV+ Abnormal Provides Predicts Genomic Global National Source: *2013 - Launched Regress Cancer Validation Luhn the cancer Cancer critical Amplification toprogression Genetics, Normal 10% Outside etNew effects al., Institute information Partners Progress IPV Genomic Grade U.S.
Slide 16: IP Position
IP Position Panel Cortical Europe Using US Canada Gynecological Tool Neoplasms ?Europe ?India ?Canada Methods Associated ?US Strong ?PCT/US2011/050681 IP-based Validation Filing 201311/932,422 Issued 12/980,480 13/475,034 13/227,027 13/474,111 for Cancer for Fluorescence and 6657/DELNP/2012 and 0884
Slide 17: Commercialization Strategy
Large, Target Universities Community Regional Oncologists Biotechnology Pharmaceutical Emerging Commercialization Collaborate Accelerate Continue Plan Leverage Expand Enhance Partner 2013 development Cancer Markets Targeted with sales distributor Cancer to clinical Markets launch to growing and Hosp
Slide 18: Expanding Opportunity in Community Hospitals
Unique Expanding 4,000 85% $600,000—$800,000 Source: Delivers Enables Brings Allows Improving 2013 Of Cancer topersonalized community Service American All community 5,000 better care &U.S. Genetics, Developing Community outcomes and Offering Cancer Hospital hospitals quality medicine hospitals USD I
Slide 19: Clinical Trial Services Growth
Clinical ONCOLOGY WITH $684 2011 Source: Well-Positioned 2013 2016 21% Cancer BIOMARKER(S) Company Trial $221 1H,Genetics, Services DRUGS 2011 forAnalysis Use 1H, Showing Inc. ASSOCIATED in 2012 CLIENTS Clinical |and OTCQB: 1H, Management Strong 2013 Trials ($000) CGIX GROWTH Growth &$1,738 Companio
Slide 20: Gilead Relationship Highlights
Gilead Comprehensive, Highlights Testing CGI The CGI’s CGIX 2013 Gilead provides Cancer Select Press iswill Currently Relationship occur Release: Genetics, One™ biomarker biomarker-based across Using Offering Cancer Inc. driven Exemplifies several a |Comprehensive OTCQB: Genetics, insight methodolog
Slide 21: Collaborations Driving Product Adoption
Collaborations Leading Research Renal Joint DLBCL Cervical Kidney DLBCL, 2013 CLL Venture Cancer Cancer, Cancer Differentiated Cancer Head Collaboration/ Genetics, Focused DLBCL, & with &Neck DLBCL Premier on Inc. Research Cancers MCL Clinical Oncology | OTCQB: Cancer & FL & Partnership Driving & Re
Slide 22: International Expansion Through Partnerships
Well-Positioned International Expect We Expanded Continued 2013focus Cancer exposure our distribution focus Genetics, revenue efforts and on to increase increasing Growing through comes network Inc. | to OTCQB: from partnerships Internationally international emerging with sale 4 new CGIX of economie
Slide 23: Roche Expanding CGI Market Presence Internationally
Roche Expanding CGI Highlights interacts “Since This Alvaro CGIX 2013 will won commitment Cancer Press Partnership the Soto, with be abeginning, Market global providing Release: Genetics, Roche bothwith RFP Roche Presence Servicios Cancer CGI genomic Inc. Roche to help and understood | International
Slide 24: Mayo Clinic Joint Venture: OncoSpire Genomics
Investing Next JV Highlights over Mayo The CGIX 2013 toValue initial Generation Cancer develop Clinic commits Press inand three the Release: Joint Genetics, clinical Focus to Future year Sequencing “in-kind” Venture of Mayo period diagnostic Inc. –Next OncoSpire |Clinic services OTCQB: (2013 in Gene
Slide 25: Strong Revenue and Clinical Volume Growth
Strong CGI Total Clinical $3.02 5,115 $4.30 6,610 $2.52 $1.67 *2009 Trailing 2013 Estimated Revenue 2010 Cancer Revenue $3.00 3,622 2,321 History Volume 12 2011 Months 3,146 Genetics, &($Mn) of2012 (Tests Clinical Growth Revenue 1H-2013* Inc. Processed) Volume | OTCQB: $5. Mn* 2009 Trends CGIX 2010
Slide 26: Quarterly Revenue and Volume Comparison
Strong (Quarterly Total Clinical $1,750 97% 52% $1,219 1,610 1,911 Grants** *2012 ** Grants 2013 Estimated Grants 46% 2013 Cancer Revenue 1,623 Q2,2012: History 3,204 $1,148 Volume Grants** 19% Q1,2012: Comparison 2012 Note: $835 Genetics, ($000) of(Tests 2013* $185K Growth—Revenue Approx. $10K Inc.
Slide 27: Summary Income Statement (2009-2013)
Summary (2009-2013 Income Revenue Research Sales General $Operating *2009—2012 2013 in thousands Estimated Cancer & Statement Marketing &$1,666 &Statement Profit Administrative thru Development audited Genetics, $2,522 (Loss) 6 Item mos) (S&M) of Inc. Operations 2009 (4,286) $3,019 (R&D) (G&A) 239 |
Slide 28: Summary Income Statement (Quarterly)
Summary (Quarterly Income Revenue *Research 2013 Estimated Cancer Statement $1,148 &Statement &Development $Genetics, First in $1,750 thousands Item Half of Inc. Operations Comparisons Q2 52% (R&D) 2012 | OTCQB: $1,983 Q2 5272013 $3,000 2012 — CGIX 1,050 ?% vs. 51% | 1H 28 2013) —Sales Gross 2012 1H
Slide 29: Consistent Gross Margin Improvement
Consistent Additional Gross Thousands 0(800 200 9% (200) (39%) Highlights 2010 (1,000) 2009 (800) (600) (400) Manufacturing Increased Process Capacity Leveraging *Developing 2009-2012 2013 52%) Estimated Cancer 2011 Profit (3%) improvement utilization automation of Focus Efforts audited 600 cloud in
Slide 30: Multiple Payor and Customer Mix
Multiple Payor 57 21% 4% 42% Direct Academic 33% Reimbursement Community Insurance Regional & Medicare 2013 Care million Q1, Cancer Revenue Bill Facilities Customer 2013 Labs Grants, Companies Biotechs covered Customer &Genetics, Mix Based Royalty lives Types Cancer 2013 Types Companies, Direct Inc.
Slide 31: Experienced Board, Officers and Advisors
Experienced Board Officers Raju 35 Major Panna 15+ Founded 9Elizabeth JPMorgan, Jane 25 Published NIH Scientific Andrea Chairman Timothy Riccardo Hans-Guido Principal Vundavalli Director, Andrew Chief 2013 yrs years years Houldsworth, grantee Chaganti, as Cancer Strategy of ofCalifano, discoveries S
Slide 32: Recent Accomplishments and Upcoming Milestones
Strong, Recent Accelerating Received MCL Finalized Launched Upcoming Increasing Launching UroGenRA MatBA CE Additional Announcing 2013Approval Cancer (Mantle Accomplishments Commercially-Focused – Agreement Next CLIA UroGenRA™ FHACT™ Oncospire covered Milestones multi-marker international news Kidne
Slide 33: Empowering Personalized Cancer Treatment
CANCER Empowering For Cancer Meadows www.cancergenetics.com further Genetics, Office GENETICS information, Personalized Complex Inc. please Cancer 201 contact Route Treatment 17usNorth at ir@cancergenetics.com Rutherford, NJ 07070 (201) 528-9200
Slide 34: Appendix: Capitalization Table; DNA Detection Methodologies
I. CGIX Appendix II. DNA Capitalization Detection Methodologies Table Utilized By CGI
Slide 35: Summary of Common Stock Capitalization
I. Some CGIX Common 6,750,778 507,610 1,926,477 4,290,691 Warrants* Options Total Excludes 440,390 *10,000 2013 Summary Cancer –Cap shares Fully of –options 450,390: Stock Average –the Table Capitalization Average Genetics, Diluted issuable warrants reserved AsExercise of Exericse Pre-Offering to In
Slide 36: DNA Detection Methodologies Utilized By CGI
Expanding DNA-FISH Low Mid-High Existing High Low-Mid Value: Natural Fragment DNA Very The Emerging 2013Next Resolution High Resolution Cancer Microarray Next High Growing Extension CGI & Market Market Resolution Generation Proprietary Probe in Hybridize Genetics, Capabilities established in (~1-2Mb